VRTX Vertex Pharmaceuticals Incorporated

NASDAQ
$520.66

Vertex Pharmaceuticals Incorporated (VRTX) is expected to report earnings on February 1, 2027, after the market close. The consensus earnings estimate is $3.59 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -6.8% since its last earnings release on November 2, 2026.

Vertex Pharmaceuticals Missed Expectations, Raises Guidance In-line with Estimates
Monday, November 2, 2026 · 4:01 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 1
Monday · 4:00 PM ET
Earnings Whisper
-
vs $3.59 (GAAP)
Rev est $3.48B
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $540.17

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Inc is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.